The Role of the Hematologist/Oncologist in the Care of Patients with Vascular Anomalies

Pediatric Clinics of North America

Volumn 55, Issue 2, 2008, Pages 339-355

  Adams, Denise M ^a,b   Wentzel, Mary Sue ^b  

^a UNIVERSITY OF CINCINNATI   (United States)

^b CINCINNATI CHILDREN'S HOSPITAL MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AMINOCAPROIC ACID; ANTICOAGULANT AGENT; ANTIFIBRINOLYTIC AGENT; ANTINEOPLASTIC AGENT; ANTIVITAMIN K; BECAPLERMIN; BEVACIZUMAB; CORTICOSTEROID DERIVATIVE; COTRIMOXAZOLE; CYCLOPHOSPHAMIDE; DACTINOMYCIN; ENOXAPARIN; GEFITINIB; GLUCOCORTICOID; HEPARIN; IMATINIB; IMIQUIMOD; LENALIDOMIDE; LOW MOLECULAR WEIGHT HEPARIN; PREDNISOLONE; PROTON PUMP INHIBITOR; RANITIDINE; RETINOID DERIVATIVE; STEROID; THALIDOMIDE; TRANEXAMIC ACID; UNINDEXED DRUG; VASCULOTROPIN INHIBITOR; VINCRISTINE; WARFARIN;

ANTIBIOTIC PROPHYLAXIS; ARTHRALGIA; BLEEDING; BLOOD CLOTTING DISORDER; BODY HEIGHT; CARDIOMYOPATHY; CLINICAL FEATURE; CLINICAL PRACTICE; CLINICAL TRIAL; CONGENITAL BLOOD VESSEL MALFORMATION; CONGESTIVE HEART FAILURE; CONSTIPATION; CONTROLLED CLINICAL TRIAL; CROHN DISEASE; CUSHINGOID SYNDROME; DIAGNOSTIC PROCEDURE; DISEASE PREDISPOSITION; DISEASE SEVERITY; DOSE RESPONSE; DRUG EFFICACY; DRUG HALF LIFE; DRUG MECHANISM; DRUG TOLERABILITY; ELECTROLYTE DISTURBANCE; EYE DISEASE; HEALTH CARE PERSONNEL; HEMANGIOMATOSIS; HUMAN; HYPERGLYCEMIA; HYPERTENSION; IMMUNE DEFICIENCY; INCIDENCE; IRRITABILITY; MULTIPLE MYELOMA; MYCOSIS; MYOPATHY; MYOSITIS; NEUROLOGIC DISEASE; OSTEOPENIA; OSTEOPOROSIS; PATIENT CARE; PERIPHERAL NEUROPATHY; PERSONALITY DISORDER; PNEUMOCYSTOSIS; PROTEINURIA; RANDOMIZED CONTROLLED TRIAL; REVIEW; SCLEROTHERAPY; SIDE EFFECT; SINGLE DRUG DOSE; SOLID TUMOR; STOMACH IRRITATION; STROKE; THROMBOEMBOLISM; THROMBOPHILIA; THROMBOSIS; TISSUE INJURY; TREATMENT DURATION; TREATMENT INDICATION; TREATMENT OUTCOME; TREATMENT RESPONSE; TUMOR CLASSIFICATION; VASCULAR TUMOR; WEIGHT REDUCTION;

ARTERIOVENOUS MALFORMATIONS; CHILD; HEMATOLOGY; HUMANS; MEDICAL ONCOLOGY; PHYSICIAN'S ROLE; VASCULAR NEOPLASMS;

EID: 41149112007     PISSN: 00313955     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.pcl.2008.01.007     Document Type: Review

References (63)

1. Mulliken J.B., and Glowacki J. Hemangiomas and vascular malformations in infants and children: a classification based on endothelial characteristics. Plast Reconstr Surg 69 3 (1982) 412-422
2. Fishman S.J., and Mulliken J.B. Vascular anomalies. A primer for pediatricians. Pediatr Clin North Am 45 6 (1998) 1455-1477
3. Enjolras O., and Mulliken J.B. Vascular tumors and vascular malformations (new issues). Adv Dermatol 13 (1997) 375-423
4. Drolet B., Esterly N., and Frieden I.J. Hemangiomas in children. N Engl J Med 341 3 (1999) 173-181
5. Haggstrom A.N., Drolet B.A., Baselga E., et al. Prospective study of infantile hemangiomas: clinical characteristics predicting complications and treatment. Pediatrics 118 (2006) 882-887
6. Mulliken J.B., and Enjoras O. Congenital hemangiomas and infantile hemangioma: missing links. J Am Acad Dermatol 50 6 (2004) 875-882
7. North P.E., Waner M., Mizeracki A., et al. GLUT 1: a newly discovered immunohistochemical marker for juvenile hemangiomas. Human Pathology 31 1 (2000) 11-22
8. Orlow S.J., Isakoff M.S., and Blei F. Increased risk of symptomatic hemangiomas of the airway in association with cutaneous hemangiomas in a "beard" distribution. J Pediatr 131 (1997) 643-646
9. Stockman A., Boralevi F., Taieb A., et al. SACRAL syndrome: spinal dysraphism, anogenital, cutaneous, renal and urologic anomalies, associated with an angioma of lumbosacral localization. Dermatology 214 1 (2007) 40-45
10. Drolet B., and Garzon M. SACRAL syndrome. Dermatology 215 4 (2007) 360-361
11. Isaacs Jr. H. Fetal and neonatal hepatic tumors. J Pediatr Surg 42 11 (2007) 1789-1803
12. Sari N., Yalcin B., Akuyuz C., et al. Infantile hepatic hemangioendothelioma with elevated serum alpha-fetoprotein. Pediatr Hematol Oncol 23 8 (2006) 639-647
13. Christison-Lagay E.R., Burrows P.E., Alomari A., et al. Hepatic hemangiomas:subtype classification and development of a clinical algorithm and registry. J Pediatr Surg 42 1 (2007) 62-67
14. Mehrabi A., Kashfi A., Fonauni H., et al. Primary malignant hepatic epithelioid hemangioendothelioma: a comprehensive review of the literature with emphasis on the surgical therapy. Cancer 107 9 (2006) 2108-2121
15. Nord K.M., Kandel J., Lefkowitch J.H., et al. Mulitple cutaneous infantile hemangiomas associated with hepatic angiosarcoma: case report and review of the literature. Pediatrics 118 3 (2006) 907-913
16. Lu M., and Greer M.L. Hypervascular multifocal hepatoblastoma:dynamic gadolinium-enhanced MRI findings indistinguishable from infantile hemangioendothelioma. Pedriatr Radiol 37 6 (2007) 587-591
17. Huang S.A., Tu H.M., Harney J.W., et al. Severe hypothyroidism caused by type 3 iodothyronine deiodinase in infantile hemangiomas. N Engl J Med 343 3 (2000) 185-189
18. Kalpatthi R., Germak J., Mizelle K., et al. Thyroid abnormalities in infantile hepatic hemangioendothelioma. Pediatr Blood Cancer 49 7 (2007) 1021-1024
19. Bronzetti G., Giardini A., Patrizi A., et al. Ipsilateral hemangioma and aortic arch anomalies in posterior fossa malformations, hemangiomas, arterial anomalies, coarctation of the aorta, and cardiac defects and eye abnormalities (PHACE) anomaly: report and review. Pediatrics 113 (2004) 412-415
20. Metry D.W., Dowd C.F., Barkovich A.J., et al. The many faces of PHACE syndrome. J Pediatr 139 (2001) 117-123
21. Metry D.W., Haggstrom A.N., Drolet B.A., et al. A prospective study of PHACE syndrome in infantile hemangiomas: demographic features, clinical findings, and complications. Am J Med Genet A 140 (2006) 975-986
22. Kasabach H., and Merritt K. Capillary hemangioma with extensive purpura: report of a case. Am J Dis Child 59 (1940) 1063-1070
23. Sarkar M., Mulliken J.B., Kozakewich H.P., et al. Thrombocytopenic coagulopathy (Kasabach-Merritt phenomenon) is associated with Kaposiform hemangioendothelioma and not with common infantile hemangioma. Plast Reconstr Surg 100 6 (1997) 1377-1386
24. Enjolras O., Wassef M., Mazoyer E., et al. Infants with Kasabach-Merritt syndrome do not have "true" hemangiomas. J Pediatr 130 4 (1997) 631-640
25. Gruman A., Liang M.G., Mulliken J.B., et al. Kaposiform hemangioendothelioma without Kasabach-Merritt phenomenon. J Am Acad Dermatol 52 4 (2005) 616-622
26. Haisley-Royster C., Enjolras O., Freden J.J., et al. Kasabach-merritt phenomenon: a retrospective study of treatment with vincristine. J Pediatr Hematol Oncol 24 6 (2002) 459-462
27. Mulliken J.B., Anupindi S., Ezekowitz R.A.B., et al. Case 13-2004: a newborn girl with a large cutaneous lesion, thrombocytopenia, and anemia. N Engl J Med 350 (2004) 1764-1775
28. Hauer J., Graubner U., Konstantopoulos N., et al. Effective treatment of kaposiform hemangioendotheliomas associated with Kasabach-Merritt phenomenon using four-drug regimen. Pediatr Blood Cancer 49 6 (2007) 852-854
29. Enjolras O., Mulliken J.B., Wassef M., et al. Residual lesions after Kasabach-Merritt phenomenon in 41 patients. J Am Acad Dermatol 42 (2000) 225-235
30. Adams D. Hemangioma and vascular malformations center. Available at: http://www.cincinnatichildrens.org/svc/alpha/h/vascular. Accessed March 11, 2008.
31. Enjolras O., Riche M.C., Merland J.J., et al. Management of alarming hemangiomas in infancy: a review of 25 cases. Pediatrics 85 4 (1990) 491-498
32. Bartoshesky L.E., Bull M., and Ferngold M. Corticosteroid treatment of cutaneous hemangiomas: how effective? A report on 24 children. Clin Pediatr (Phila) 17 8 (1978) 629-638
33. Brown Jr. S.H., Neerhout R.C., and Fonkalsrud E.W. Prednisone therapy in the management of large hemangiomas in infants and children. Surgery 71 2 (1972) 168-173
34. Hasan Q., Tan S.T., Gush J., et al. Steroid therapy of a proliferating hemangioma: histochemical and molecular changes. Pediatrics 105 (2000) 117-120
35. Maronn M.L., Corden T., and Drolet B.A. Pneumocystis carinii pneumonia in infant treated with oral steroids for hemangioma. Arch Dermatol 143 9 (2007) 1224-1225
36. Boon L.M., MacDonald D.M., and Muliken J.B. Complications of systemic corticosteroid therapy for problematic hemangioma. Plast Reconstr Surg 104 6 (1999) 1616-1623
37. Adams D.M. The nonsurgical management of vascular lesions. Facial Plast Surg Clin North Am 9 (2001) 601-608
38. Adams DM, Orme L, Bowers D. Vincristine treatment of complicated hemangiomas. 14th International Workshop on Vascular Anomalies, Netherlands, June 2002.
39. Enjolras O., Breviere G.M., Roger G., et al. Vincristine treatment for function- and life-threatening infantile hemangioma. Arch Pediatr 11 (2004) 99-107
40. Fawcett S.L., Grant I., Hall P.N., et al. Vincristine as a treatment for a large haemangioma threatening vital functions. Br J Plast Surg 57 2 (2004) 168-171
41. Perez-Valle S., Peinador M., Herraiz P., et al. Vincristine, an efficacious alternative for diffuse neonatal haemangiomatosis. Acta Paediatr (2007) [epub ahead of print]
42. Ezekowitz R., Mulliken J.B., and Folkman J. Interferon alfa-2a therapy for life-threatening hemangiomas of infancy. N Engl J Med 326 22 (1992) 1456-1463
43. Chang E., Boyd A., Nelson C.C., et al. Successful treatment of infantile hemangiomas with interferon-alpha-2b. J Pediatr Hematol Oncol 19 3 (1997) 237-244
44. Barlow C.F., Priebe C.J., Mulliken J.B., et al. Spastic diplegia as a complication of interferon Alfa-2a treatment of hemangiomas of infancy. J Pediatr 132 3 Pt 1 (1998) 527-530
45. Michaud A.P., Bauman N.M., Burke D.K., et al. Spastic diplegia and other motor disturbances in infants receiving interferon-alpha. Laryngoscope 114 7 (2004) 1231-1236
46. List A.F. Lenalidomide-the phoenix rises. N Engl J Med 357 21 (2007) 2183-2186
47. Benesch M., Windelberg M., Sauseng W., et al. Compassionate use of bevacizumab (Avastin ®) in children and yound adults with refractory or recurrent solid tumors. Ann Oncol (2007) [epub ahead of print]
48. Hazen P.G., Carney J.F., Engstrom C.W., et al. Proliferating hemangioma of infancy: successful treatment with topical 5% imiquimod cream. Pediatric Dermatology 22 3 (2005) 254-256
49. Metz B.J., Rubenstein M.C., Levy M.L., et al. Response of ulcerated perineal hemangiomas of infancy to becaplermin gel, a recombinant human platelet-derived growth factor. Arch Dermatol 140 7 (2004) 867-870
50. In: Mulliken J.B., and Young A.E. (Eds). Vascular birthmarks: hemangiomas and malformations (1988), WB Saunders, Philadelphia
51. Enjolras O., Ciabrini D., Mazoyer E., et al. Extensive pure venous malformations in the upper or lower limb: a review of 27 cases. J Am Acad Dermatol 36 (1997) 219-225
52. Mazoyer E., Enjolras O., Laurian C., et al. Coagulation abnormalities associated with extensive venous malformations of the limbs: differentiation from Kasabach-Merritt syndrome. Clin Lab Haematol 24 4 (2002) 243-251
53. Mason K.P., Neufeld E.J., Karian V.E., et al. Coagulation abnormalities in pediatric and adult patients after sclerotherapy or embolization of vascular anomalies. AJR Am J Roentgenol 177 (2001) 1359-1363
54. Nowak-Gottl U., Junker R., Kreuz W., et al. Risk of recurrent venous thrombosis in children with combined prothrombotic risk factors. Blood 97 (2001) 858-862
55. Tormene D., Simioni P., Prandoni P., et al. The incidence of venous thromboembolism in thrombophilic children: a prospective cohort study. Blood 100 (2002) 2403-2405
56. Austin H., Key N.S., Benson J.M., et al. Sickle cell trait and the risk of venous thromboembolism among blacks. Blood 110 3 (2007) 908-912
57. Decousus H., Moulin N., Quenet S., et al. Thrombophilia and risk of venous thrombosis in patients with cancer. Thromb Res 120 Suppl 2 (2007) S51-S61
58. Skourtis G., Lazoura O., Panoussis P., et al. Klippel-Trenaunay syndrom:an unusual cause of pulmonary embolism. Int Angiol 25 3 (2006) 322-326
59. Huiras E.E., Barnes C.J., Eichenfield L.F., et al. Pulmonary thromboembolism associated with Klippel-Trenaunay syndrome. Pediatrics 116 4 (2005) e596-e600
60. Morad A.B., McClain K.L., and Ogden A.K. The role of tranexamic acid in the treatment of giant hemangiomas in newborns. Am J Pediatr Hematol Oncol 15 (1993) 383-385
61. Wang Q.K. Update on the molecular genetics of vascular anomalies. Lymphat Res Biol 3 4 (2005) 226-233
62. Tan W.H., Baris H.N., Burrows P.E., et al. The spectrum of vascular anomalies in patients with PTEN mutations: implications for diagnosis and management. J Med Genet 44 9 (2007) 594-602
63. O'Reilly K.E., Rojo F., She Q.B., et al. mTOR inhibition induces upstream receptor tyrosine kinase signaling and activates Akt. Cancer Res 66 3 (2006) 1500-1508